Management ChangeJun 30, 2026, 08:02 AM
LB Pharmaceuticals Appoints Christopher Zergebel SVP, Clinical Ops
AI Summary
LB Pharmaceuticals Inc announced the appointment of Christopher Zergebel as Senior Vice President, Clinical Operations. Mr. Zergebel brings over 25 years of global development operations experience, including his previous role as VP at Cellectis Biologics. He will be instrumental in advancing the company's lead product candidate, LB-102, which currently has Phase 3 and Phase 2 trials underway for schizophrenia and bipolar depression, respectively, with another Phase 2 trial planned for adjunctive major depressive disorder.
Key Highlights
- LB Pharmaceuticals appointed Christopher Zergebel as Senior Vice President, Clinical Operations.
- Mr. Zergebel brings over 25 years of global development operations experience.
- He previously served as Vice President, Development Operations at Cellectis Biologics.
- His expertise will support the execution of multiple clinical programs for LB-102.
- LB-102 has a Phase 3 trial underway for schizophrenia.
- LB-102 has a Phase 2 trial underway for bipolar depression.
- A Phase 2 trial for adjunctive major depressive disorder is planned for early next year.
Price Impact
More from LBRX